Pomalidomide-C3-I

Background Introduction

Pomalidomide-C3-I is a state-of-the-art E3 ligase ligand-linker conjugate designed for use in targeted protein degradation research. As an essential building block in PROTAC (Proteolysis Targeting Chimera) technology, this molecule features pomalidomide—a thalidomide analog recognized for its binding to the E3 ubiquitin ligase cereblon (CRBN)—connected via a three-carbon (C3) linker. Its modular design facilitates the rapid development of next-generation PROTACs and molecular glues for both academic and drug discovery applications.

Mechanism

The mechanism of action of Pomalidomide-C3-I centers on leveraging the ubiquitin-proteasome system. The pomalidomide moiety effectively recruits the CRBN E3 ubiquitin ligase complex, while the C3 linker provides a versatile handle for conjugation to a ligand targeting the protein of interest. Once incorporated into a PROTAC molecule, Pomalidomide-C3-I mediates proximity-induced ubiquitination, resulting in selective proteasomal degradation of the target protein. This innovative approach enables the removal of disease-relevant or hard-to-drug proteins at the post-translational level, differentiating PROTACs from traditional small-molecule inhibitors.

Applications

Pomalidomide-C3-I is widely utilized as a chemical intermediate for designing and synthesizing CRBN-based PROTACs and related heterobifunctional degraders. It supports target identification, lead optimization, and mechanistic studies in preclinical research. Applications include advancing cancer therapy, neurodegenerative disease models, and other pathogenic contexts where selective protein knockdown is desirable. Additionally, Pomalidomide-C3-I is valuable for academic research exploring targeted protein degradation pathways and structure-activity relationship (SAR) profiling of novel degrader molecules.

The *Pomalidomide-C3-I* E3 Ligase Ligand-Linker Conjugate plays a pivotal role in the development of PROTACs by facilitating targeted protein degradation. This conjugate combines a pomalidomide-based ligand with a C3 alkyl linker, optimizing the interaction between the E3 ligase and the target protein, thereby enhancing the efficacy and specificity of protein degradation processes.

Linker: The C3 alkyl linker in this molecule is characterized by its moderate length and flexibility, which allows for optimal spatial arrangement between the ligand and the target protein. This linker is non-cleavable, ensuring stability and sustained interaction throughout the degradation process.

Ligand: The ligand component of this molecule is derived from pomalidomide, a well-known thalidomide analog. It features a glutarimide ring, which is essential for binding to the cereblon E3 ligase substrate receptor, facilitating targeted protein ubiquitination and subsequent degradation.

Reactive Site: The reactive site in this molecule is located at the terminal end of the linker, equipped with an iodine atom for coupling with the target protein ligand. Recommended reaction types include nucleophilic substitution reactions, which efficiently link the conjugate to the target protein warhead.

Recommended Target Protein Ligand: The ideal warhead for this conjugate is a small molecule inhibitor or binder with a nucleophilic group, such as an amine or thiol, which can form a stable covalent bond with the reactive site. This compatibility ensures precise targeting of proteins involved in disease pathways, offering significant advantages in experimental studies aimed at elucidating protein function and therapeutic potential.